[2] Li Y, Abudureheiyimu N, Mo H, et al. In Real Life, Low-Level HER2 Expression May Be Associated With Better Outcome in HER2-Negative Breast Cancer: A Study of the National Cancer Center, China. Front Oncol. 2022 Jan 17;11:774577. [3] Rossi V, Sarotto I, Maggiorotto F, e...
[7]Li, Y. et al. In real life, low-level HER2 expression may be associated with better outcome in HER2 negative breast cancer: A study of the National Cancer Center, China. Front. Oncol. https://doi.org/10.3389/fonc.2021.774577 (2021). [8]Rosso, C. & Voutsadakis, I. A. Character...
参考文献: [1]Wang J, Liu Y, Liang Y, et al. Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients....
[12]Marra A, Goldfinger M, Millar E, et al. 93P An AI-driven computational biomarker from H&E slides recovers cases with low levels of HER2 from immunohistochemically HER2-negative breast cancers. Ann Oncol 2022;33:581. [13]Atall...
[17]Peter Schmid, et al. Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/mTNBC) . 2023 ESMO Abstract 379MO.
近日,一篇发表在国际杂志Nature Cancer上题为“Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial”的研究报告中,来自美国约翰霍普金斯医学院等机构的科学家们通过研究发现,一种新型三种药物组合疗法或在晚期HER2阴性乳腺癌的治疗中取得了显著的疗效。这种疗法...
《Clinical Cancer Research》于2022年8月31日在线发表了《Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-positive, HER2-negative Primary Breast Cancer》研究评价了EndoPredict 在绝经前女性中的评估可靠性 管腔雌激素受体阳性 (ER+)、人表皮生长因子2阴性 (HER2-)乳腺癌(BC)是 BC 中最常诊...
1. FDA Accepts BLA for Dato-DXd in HR+/HER2– Breast Cancer (targetedonc.com) 2. Datopotamab deruxtecan significantly extended progression-free survival vs. chemotherapy in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial (astrazeneca.com) ...
SAJI S, TAIRA N, KITADA M, et al. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial [J]. Lancet Oncol, 2022, S1470-2045(...
2. Hurvitz S A, Bardia A, Punie K, et al. 168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: findings from the phase III ASCENT study[J]. Annals of Oncology, 2022, 33: S200-S201. ...